Decision to remove the Xpharm restriction from the Poliomyelitis and Hepatitis B Vaccines
What we’re doing
We're pleased to announce the Xpharm restriction will be removed from the following vaccines in Section I of the Pharmaceutical Schedule from 1 December 2026:
- Poliomyelitis vaccine
- IPOL
- Hepatitis B Vaccine
- Engerix B (adult)
- Engerix B (paediatric)
Removing the Xpharm restriction is a technical change to the Pharmaceutical Schedule that will allow pharmacies and other providers to claim reimbursement for these vaccinations. No changes have been made to supply and distribution arrangements for other vaccines on the Pharmaceutical Schedule.
Why we’re proposing this
Vaccines are distributed differently to most other funded medicines in New Zealand. The Xpharm restriction means that pharmacies cannot claim subsidy for the funded product. Therefore, pharmacists and Plunket providers are not currently able to provide these vaccinations. When Pharmac removed Xpharm from childhood vaccines in 2024 the Xpharm restriction was left on certain low usage vaccines, including the poliomyelitis vaccine and the two hepatitis B vaccines. The restriction remained on these vaccines due to the low usage and the high risk of wastage if many pharmacies held stock.
Health NZ has since identified a need for these vaccines to be made available without the Xpharm restriction to a small number of pharmacies and Plunket providers. This decision will make it easier for the small number of people who need the IPOL or Engerix B vaccines to access them in the community.
Who we think will be most interested
- Healthcare professionals working in primary care and outreach vaccination settings including pharmacists, Well Child Tamariki Ora providers, Hauora Māori providers, Pacific Health providers, Midwifery services, Plunket providers
- Paediatricians
- Infectious disease
- Health New Zealand
- Suppliers and wholesalers
- Organisations with an interest in immunisation, including Ministry of Health, Public Health Agency, Immunisation Advisory Centre (IMAC)
Detail about this decision
Section I changes
The following changes will occur in Section I of the Pharmaceutical Schedule from 1 December 2026.
Poliomyelitis vaccine:
(additions in bold):
a) Only on a prescription
b) No patient co-payment payable
c)
A) Up to three doses for patients meeting either of the following:
1. For partially vaccinated or previously unvaccinated individuals; or
2. For revaccination following immunosuppression.
B) Contractors will be entitled to claim payment from the Funder for the supply of Poliomyelitis vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Poliomyelitis vaccine listed in the Pharmaceutical Schedule.
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.
Hepatitis B recombinant vaccine inj 10 mcg per 0.5 ml prefilled syringe:
(additions in bold):
a) Only on a prescription
b) No patient co-payment payable
A) Funded for patients meeting any of the following criteria:
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4) for HIV positive patients; or
5) for hepatitis C positive patients; or
6) for patients following non-consensual sexual intercourse; or
7) for patients prior to planned immunosuppression for greater than 28 days; or
8) for patients following immunosuppression; or
9) for solid organ transplant patients; or
10) for post-haematopoietic stem cell transplant (HSCT) patients; or
11) following needle stick injury.
B) Contractors will be entitled to claim payment from the Funder for the supply of Hepatitis B recombinant vaccine Inj 10 mcg per 0.5 ml prefilled syringe to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Hepatitis B recombinant vaccine Inj 10 mcg per 0.5 ml prefilled syringe listed in the Pharmaceutical Schedule.
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.
Hepatitis B recombinant vaccine inj 20 mcg per 1 ml prefilled syringe:
(additions in bold):
A) Funded for patients meeting any of the following criteria:
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4) for HIV positive patients; or
5) for hepatitis C positive patients; or
6) for patients following non-consensual sexual intercourse; or
7) for patients prior to planned immunosuppression for greater than 28 days; or
8) for patients following immunosuppression; or
9) for solid organ transplant patients; or
10) for post-haematopoietic stem cell transplant (HSCT) patients; or
11) following needle stick injury; or
12) for chronic kidney disease (CKD) stage 4 or 5 patients; or
13) for liver or kidney transplant patients.
B) Contractors will be entitled to claim payment from the Funder for the supply of Hepatitis B recombinant vaccine Inj 20 mcg per 1 ml prefilled syringe to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Hepatitis B recombinant vaccine Inj 20 mcg per 1 ml prefilled syringe listed in the Pharmaceutical Schedule.
C) Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.
No public consultation was undertaken on this decision as it will allow access to a wider range of vaccination sites for people eligible to receive IPOL or Hepatitis B vaccines. This will have limited impact beyond the small number of providers who will access these vaccines.
We consulted on the removal of Xpharm from all childhood vaccines in 2024 and received requests to remove Xpharm restrictions from additional vaccines including the poliomyelitis and Hepatitis B recombinant vaccines. This decision responds to these requests.
As use of these vaccines are very low, the National Vaccine Store does not carry a lot of stock. There were concerns that if many pharmacies chose to carry stock, it could result in supply issues and high wastage if doses were not used. Health NZ will manage the release of poliomyelitis and hepatitis B vaccines stock on demand to vaccinators with eligible individuals through the Health NZ vaccines store. This mitigates the risk of widespread stockholding in pharmacies without an identified eligible individual.
If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll-free number (9 am to 5 pm, Monday to Friday) on 0800 660 050.